自动化骨扫描指数预测新诊断转移性前列腺癌放疗应答:STAMPEDE M1|RT探索性分析
本研究为STAMPEDE「M1|RT比较」的探索性分析,回顾性计算660例新诊断转移性前列腺癌患者的基线自动化骨扫描指数(aBSI),评估其预测前列腺放疗生存获益的价值。中位随访39个月,aBSI与治疗交互作用对总生存(p=0.04)和无失败生存(p<0.01)均有统计学意义,低aBSI患者从放疗中获益最大。
要点
- 低aBSI预示新诊断转移性前列腺癌患者可从前列腺放疗中获得生存获益。
- aBSI与治疗交互作用对OS(p=0.04)和FFS(p<0.01)均有统计学意义。
- aBSI四分位分析支持低aBSI患者放疗获益更大这一发现。
核心结论
- 低自动化骨扫描指数可预测新诊断转移性前列腺癌患者接受前列腺放疗的生存获益。
研究设计与样本
- STAMPEDE「M1|RT比较」的探索性分析,患者1:1随机分配至标准治疗(SOC)或SOC+前列腺放疗。
- 2061例随机患者中660例(SOC组323例,SOC+放疗组337例)基线骨扫描符合aBSI计算软件要求。
- 中位年龄68岁,中位PSA 100 ng/mL,中位aBSI 0.9,中位随访39个月。
主要发现
- 采用MFPI程序评估,aBSI与治疗交互作用对总生存有统计学意义(p=0.04)。
- aBSI与治疗交互作用对无失败生存有统计学意义(p<0.01)。
- 估计治疗效应图显示,低aBSI患者从前列腺放疗中获得的OS和FFS获益最大。
- 基于aBSI四分位的进一步分析支持上述发现。
临床怎么用
- 广泛使用的骨扫描可通过自动化技术评估,或可用于筛选可能从前列腺放疗中获益的新诊断转移性前列腺癌患者。
局限性
- 本文为探索性分析,基线骨扫描为回顾性评估。
- 2061例随机患者中仅660例基线骨扫描符合aBSI计算软件要求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, but enumeration of bone metastases is limited by interobserver variations, and it does not account for metastasis volume or lesional coalescence. The automated bone scan index (aBSI) is a quantitative method of evaluating bone metastatic burden in a standardised and reproducible manner. OBJECTIVE: To evaluate whether aBSI has utility as a predictive imaging biomarker to define a newly diagnosed metastatic prostate cancer population that might benefit from the addition of prostate RT to standard of care (SOC) systemic therapy. DESIGN, SETTING, AND PARTICIPANTS: This is an exploratory analysis of men with newly diagnosed metastatic prostate cancer randomised in a 1:1 ratio to either SOC or SOC + prostate RT within the STAMPEDE "M1|RT comparison". INTERVENTION: The SOC was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December 2015. Men allocated RT received either a daily or a weekly schedule that was nominated before randomisation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline bone scans were evaluated retrospectively to calculate aBSI. We used overall (OS) and failure-free (FFS) survival as the end points. Treatment-aBSI interaction was evaluated using the multivariable fractional polynomial interaction (MFPI) and subpopulation treatment effect pattern plot. Further analysis was done in aBSI quartiles using Cox regression models adjusted for stratification factors. RESULTS AND LIMITATIONS: Baseline bone scans for 660 (SOC: 323 and SOC + RT: 337) of 2061 men randomised within the "M1|RT comparison" met the software requirements for aBSI calculation. The median age was 68 yr, median PSA was 100 ng/mL, median aBSI was 0.9, and median follow-up was 39 mo. Baseline patient characteristics including aBSI were balanced between the treatment groups. Using the MFPI procedure, there was evidence of aBSI-treatment interaction for OS (p = 0.04, MFPI procedure) and FFS (p < 0.01, MFPI procedure). Graphical evaluation of estimated treatment effect plots showed that the OS and FFS benefit from prostate RT was greatest in patients with a low aBSI. Further analysis in quartiles based on aBSI supported this finding. CONCLUSIONS: A low automated bone scan index is predictive of survival benefit associated with prostate RT in men with newly diagnosed metastatic prostate cancer. PATIENT SUMMARY: The widely used bone scan can be evaluated using an automated technique to potentially select men with newly diagnosed metastatic prostate cancer who might benefit from prostate radiotherapy.
引用
- Ali A, Hoyle AP, Parker CC, et al. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison". Eur Urol Oncol. 2020. PMID: 32591246. doi:10.1016/j.euo.2020.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。